https://beyondcapitalfunds.com/insights.html What’s happening across Beyond Capital’s portfolio companies, how we think about new investments, and what we’ve learned from doing this over multiple funds. en-us Thu, 10 Sep 2026 12:00:00 +0000 https://beyondcapitalfunds.com/insights/why-we-invested-solaris-endovascular.html https://beyondcapitalfunds.com/insights/why-we-invested-solaris-endovascular.html Thu, 10 Sep 2026 11:00:00 +0000 Covered stents fail at their edges in about one case in four. Our Fund III committee backed the team that built a stent to fix exactly that. https://beyondcapitalfunds.com/insights/solaris-endovascular-cirse-2026.html https://beyondcapitalfunds.com/insights/solaris-endovascular-cirse-2026.html Thu, 10 Sep 2026 12:00:00 +0000 Six-month results from the 120-patient DEScover study: 92.7% of treated lesions still open, and a 26-point win over balloon angioplasty in the randomized arm, presented at CIRSE 2026 in Copenhagen.